ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on February 1, 2024 (the “Grant Date”), ORIC granted a total of 12,500 non-qualified stock options and 2,100 restricted stock units to two new non-executive employees who began their employment with ORIC in January 2024.